The Pharmaceutical Care Management Association announced Thursday that its members had reached an agreement with the feds to offer information on cash prices available through TrumpRx.
The commitment encompasses nine of the industry's leading pharmacy benefit managers, including the "Big Three" in CVS' Caremark, UnitedHealth Group's Optum Rx and Cigna's Express Scripts. Other participants that have signed on include Elevance Health's CarelonRx, Humana, MedImpact Healthcare Systems, Navitus Health Solutions, Prime Therapeutics, VtylOne and WellDyne.
Members covered by these PBMs will be able to see costs for drugs purchased through TrumpRx when using their plan's real-time benefit or other pricing tools, PCMA said.
The news was first reported by Fox Business, which interviewed Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D.
Oz told the outlet that the agreement offers "the kind of transparency we need to boost competition, drive down costs, and deliver better value for American patients."
The White House initially unveiled TrumpRx in February and has secured commitments from multiple drugmakers and other stakeholders to expand the platform since that launch. For example, in May, the portal added 600 generics to the list of drugs available to users, Fierce Pharma reported.
Claims about the platform's savings have been questioned, with an analysis in the New York Times finding that claims that the platform offers the "world's lowest" drug prices fell short, per Fierce Pharma.
David Marin, CEO of PCMA, said in a statement that the agreement is "a no-brainer for our industry and for American families."
"Consumers and patients are better off when they have more options and a clear view of their costs," Marin said. "If there are times when a product is cheapest on TrumpRx, patients should know that."
"This administration has embraced the use of real-time benefit tools to give patients more information, and we strongly embrace this technology," he continued. "This commitment will allow consumers to compare options and make better-informed choices about costs and where they access prescription drugs."